This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yang, C.
Right arrow Articles by Lal, A. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yang, C.
Right arrow Articles by Lal, A. A.

 Previous Article  |  Next Article 

Infection and Immunity, January 1999, p. 342-349, Vol. 67, No. 1
0019-9567/99/$00.00+0

Partial Protection against Plasmodium vivax Blood-Stage Infection in Saimiri Monkeys by Immunization with a Recombinant C-Terminal Fragment of Merozoite Surface Protein 1 in Block Copolymer Adjuvant

Chunfu Yang,1 William E. Collins,1 JoAnn S. Sullivan,1 David C. Kaslow,2 Lihua Xiao,1 and Altaf A. Lal1,*

Division of Parasitic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Public Health Service, U.S. Department of Health and Human Services, Atlanta, Georgia 30341,1 and Laboratory of Malaria Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 208922

Received 26 May 1998/Returned for modification 24 July 1998/Accepted 1 October 1998

Merozoite surface protein 1 is a candidate for blood-stage vaccines against malaria parasites. We report here an immunization study of Saimiri monkeys with a yeast-expressed recombinant protein containing the C terminus of Plasmodium vivax merozoite surface protein 1 and two T-helper epitopes of tetanus toxin (yP2P30Pv20019), formulated in aluminum hydroxide (alum) and block copolymer P1005. Monkeys immunized three times with yP2P30Pv20019 in block copolymer P1005 had significantly higher prechallenge titers of immunoglobulin G (IgG) antibodies against the immunogen and asexual blood-stage parasites than those immunized with yP2P30Pv20019 in alum, antigen alone, or phosphate-buffered saline (PBS) (P < 0.05). Their peripheral blood mononuclear cell proliferative responses to immunogen stimulation 4 weeks after the second immunization were also significantly higher than those from the PBS control group (P < 0.05). Upon challenge with 100,000 asexual blood-stage parasites 5 weeks after the last immunization, monkeys immunized with yP2P30Pv20019 in block copolymer P1005 had prepatent periods longer than those for the control alone group (P > 0.05). Three of the five animals in this group also had low parasitemia (peak parasitemia, <= 20 parasites/µl of blood). Partially protected monkeys had significantly higher levels of prechallenge antibodies against the immunogen than those unprotected (P < 0.05). There was also a positive correlation between the prepatent period and titers of IgG antibodies against the immunogen and asexual blood-stage parasites and a negative correlation between accumulated parasitemia and titers of IgG antibodies against the immunogen (P < 0.05). These results indicate that when combined with block copolymer and potent T-helper epitopes, the yeast-expressed P2P30Pv20019 recombinant protein may offer some protection against malaria.

* Corresponding author. Mailing address: Immunology Branch, Mail Stop F-12, Centers for Disease Control and Prevention, 4770 Buford Highway, Atlanta, GA 30341. Phone: (770) 488-4047. Fax: (770) 488-4454. E-mail: aal1{at}cdc.gov.

Infection and Immunity, January 1999, p. 342-349, Vol. 67, No. 1
0019-9567/99/$00.00+0


This article has been cited by other articles:

  • Collins, W. E., Sullivan, J. S., Strobert, E., Galland, G. G., Williams, A., Nace, D., Williams, T., Barnwell, J. W. (2009). Studies on the Salvador I Strain of Plasmodium vivax in Non-human Primates and Anopheline Mosquitoes. Am J Trop Med Hyg 80: 228-235 [Abstract] [Full Text]  
  • Bastos, M. S., da Silva-Nunes, M., Malafronte, R. S., Hoffmann, E. H. E., Wunderlich, G., Moraes, S. L., Ferreira, M. U. (2007). Antigenic Polymorphism and Naturally Acquired Antibodies to Plasmodium vivax Merozoite Surface Protein 1 in Rural Amazonians. CVI 14: 1249-1259 [Abstract] [Full Text]  
  • VALDERRAMA-AGUIRRE, A., QUINTERO, G., GOMEZ, A., CASTELLANOS, A., PEREZ, Y., MENDEZ, F., AREVALO-HERRERA, M., HERRERA, S. (2005). ANTIGENICITY, IMMUNOGENICITY, AND PROTECTIVE EFFICACY OF PLASMODIUM VIVAX MSP1 PV200L: A POTENTIAL MALARIA VACCINE SUBUNIT. Am J Trop Med Hyg 73: 16-24 [Abstract] [Full Text]  
  • COLLINS, W. E., GALLAND, G. G., BARNWELL, J. W., UDHAYAKUMAR, V., SULLIVAN, J. S., NACE, D., TONGREN, J. E., WILLIAMS, T., ROBERTS, J., SHI, Y. P., LAL, A. A. (2005). PRELIMINARY OBSERVATIONS ON THE EFFICACY OF A RECOMBINANT MULTISTAGE PLASMODIUM FALCIPARUM VACCINE IN AOTUS NANCYMAI MONKEYS. Am J Trop Med Hyg 73: 686-693 [Abstract] [Full Text]  
  • Dutta, S., Kaushal, D. C., Ware, L. A., Puri, S. K., Kaushal, N. A., Narula, A., Upadhyaya, D. S., Lanar, D. E. (2005). Merozoite Surface Protein 1 of Plasmodium vivax Induces a Protective Response against Plasmodium cynomolgi Challenge in Rhesus Monkeys. Infect. Immun. 73: 5936-5944 [Abstract] [Full Text]  
  • COLLINS, W. E., SULLIVAN, J. S., GALLAND, G. G., WILLIAMS, A., NACE, D., WILLIAMS, T., BARNWELL, J. W. (2005). PLASMODIUM SIMIUM AND SAIMIRI BOLIVIENSIS AS A MODEL SYSTEM FOR TESTING CANDIDATE VACCINES AGAINST PLASMODIUM VIVAX. Am J Trop Med Hyg 73: 644-648 [Abstract] [Full Text]  
  • Sachdeva, S., Ahmad, G., Malhotra, P., Mukherjee, P., Chauhan, V. S. (2004). Comparison of Immunogenicities of Recombinant Plasmodium vivax Merozoite Surface Protein 1 19- and 42-Kilodalton Fragments Expressed in Escherichia coli. Infect. Immun. 72: 5775-5782 [Abstract] [Full Text]  
  • Dutta, S., Ware, L. A., Barbosa, A., Ockenhouse, C. F., Lanar, D. E. (2001). Purification, Characterization, and Immunogenicity of a Disulfide Cross-Linked Plasmodium vivax Vaccine Candidate Antigen, Merozoite Surface Protein 1, Expressed in Escherichia coli. Infect. Immun. 69: 5464-5470 [Abstract] [Full Text]  
  • Ahlborg, N., Ling, I. T., Holder, A. A., Riley, E. M. (2000). Linkage of Exogenous T-cell Epitopes to the 19-Kilodalton Region of Plasmodium yoelii Merozoite Surface Protein 1 (MSP119) Can Enhance Protective Immunity against Malaria and Modulate the Immunoglobulin Subclass Response to MSP119. Infect. Immun. 68: 2102-2109 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»